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Promoter hypermethylation is central in deregulating gene expression in cancer. Identification of novel methylation targets in specific
cancers provides a basis for their use as biomarkers of disease occurrence and progression. We developed an in silico strategy to
globally identify potential targets of promoter hypermethylation in prostate cancer by screening for 50 CpG islands in 631 genes that
were reported as downregulated in prostate cancer. A virtual archive of 338 potential targets of methylation was produced. One
candidate, IGFBP3, was selected for investigation, along with glutathione-S-transferase pi (GSTP1), a well-known methylation target
in prostate cancer. Methylation of IGFBP3 was detected by quantitative methylation-specific PCR in 49/79 primary prostate
adenocarcinoma and 7/14 adjacent preinvasive high-grade prostatic intraepithelial neoplasia, but in only 5/37 benign prostatic
hyperplasia (Po0.0001) and in 0/39 histologically normal adjacent prostate tissue, which implies that methylation of IGFBP3 may be
involved in the early stages of prostate cancer development. Hypermethylation of IGFBP3 was only detected in samples that also
demonstrated methylation of GSTP1 and was also correlated with Gleason score X7( P¼0.01), indicating that it has potential as a
prognostic marker. In addition, pharmacological demethylation induced strong expression of IGFBP3 in LNCaP prostate cancer cells.
Our concept of a methylation candidate gene bank was successful in identifying a novel target of frequent hypermethylation in early-
stage prostate cancer. Evaluation of further relevant genes could contribute towards a methylation signature of this disease.
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Prostate cancer is the most common noncutaneous malignancy
and a leading cause of cancer-related deaths in men in the Western
world (Jemal et al, 2006). Although gland-confined disease is
potentially curable, the inevitable emergence of androgen insensi-
tivity in late-stage tumours is ultimately fatal. The molecular
events leading to the initiation and development of prostate cancer
are not well understood. High-throughout quantitative transcrip-
tomic studies have revealed large numbers of gene expression
changes (Dhanasekaran et al, 2001; Ashida et al, 2004), which
suggest that a broad and complex network of molecular alterations
is involved. In addition to deciphering the identities and functions
of these genes, it is important to address the mechanisms that
govern their deregulation.
The integral role of epigenetic mechanisms such as promoter
hypermethylation in the silencing of tumour suppressor genes has
become ever more apparent over the past decade (Herman and
Baylin, 2003). Promoter hypermethylation is widespread in
prostate cancer; described at early stages of cancer development
in preinvasive high-grade prostatic intraepithelial neoplasia
(HGPIN) and has been correlated with clinicopathologic features
indicative of a poor prognosis, indicating the potential of gene
hypermethylation as a marker of clinically significant disease
(Perry et al, 2006).
The most promising methylation biomarker identified to date
is glutathione-S-transferase pi (GSTP1), detected in 490% of
prostate tumours, 470% of HGPIN and at significantly lower
frequencies and quantitatively much lower levels in normal
prostate and benign prostatic hyperplasia (BPH) (Nakayama
et al, 2003; Jeronimo et al, 2004). In addition, methylation of
GSTP1 is highly specific to prostate cancer, rarely detected in other
tumours (Esteller et al, 2001). Glutathione-S-transferase pi is
methylated throughout all stages and grades of prostate cancer.
Therefore, the efficacy of GSTP1 as a prognostic biomarker of
clinically significant prostate cancer would undoubtedly be
improved with the discovery of further epigenetic targets in this
disease. Identifying novel targets of hypermethylation from
transcriptional data repositories may also shed insight into
potential pathways of this disease, as well as highlight individual
genes relevant to prostate carcinogenesis.
We developed an in silico strategy to globally identify potential
targets of promoter hypermethylation in prostate cancer. This
approach yielded a database of over 300 potential targets of
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smethylation in prostate cancer. Several lines of evidence supported
an investigation into the Insulin-like growth factor binding protein
3 (IGFBP3) gene. IGFBP3 is the most abundant IGF-binding
protein in the circulation, where it controls the half-life and
bioavailability of IGF1 for signal transduction through the IGF1
Receptor (IGF1R), which leads to the activation of growth
promoting pathways, including the Ras/Raf/MAP kinase and the
phosphotidylinositol-3 kinase pathways (Renehan et al, 2004;
Papatsoris et al, 2005). Overexpression of IGFBP3 has dramatic
growth-inhibitory and proapoptotic effects in murine prostate
tumours and prostate cancer cell lines (Modric et al, 2001; Devi
et al, 2002), indicating that IGFBP3 may act as a tumour
suppressor in prostate cells. IGFBP3 also exerts a variety of IGF-
independent proapoptotic and antiproliferative effects, shown
by the finding that IGFBP3 overexpression inhibits the growth of
fibroblasts that are IGF1R negative (Oh et al, 1993).
Promoter hypermethylation has been proposed as a mechanism
responsible for transcriptional silencing of IGFBP3 in hepatocellular
carcinoma (Hanafusa et al, 2002), non-small cell lung carcinoma
(Chang et al, 2002) and very recently in cancers of the bladder
and ovary (Christoph et al, 2006; Wiley et al, 2006). In this study, we
performed an extensive analysis of the methylation pattern of
IGFBP3 in benign, preinvasive and cancerous prostate tissues.
Concordance between IGFBP3 and GSTP1 methylation was investi-
gated. Statistical analysis was performed to investigate a correlation
between methylation and clinical and pathologic parameters. In
addition, prostate cancer cell lines were employed to test whether
promoter hypermethylation affects IGFBP3 gene expression.
MATERIALS AND METHODS
In silico mining to identify novel targets of methylation in
prostate cancer
We developed an in silico approach to identify potential targets of
promoter hypermethylation in prostate cancer. The principle
behind this concept was that promoter hypermethylation leads to a
reduction in gene expression at the transcriptional level. Two
freely available web-based transcriptome databases were employed
to identify genes downregulated in prostate cancer compared with
normal prostate. Nine queries were performed on the Gene
Expression Atlas (http://expression.gnf.org) to retrieve genes that
were both expressed in normal prostate 41 times – and in prostate
cancer o0.5–1 times – the median expression across 46 human
tissues (Su et al, 2001). The Digital Differential Display (http://
www.ncbi.nlm.nih.gov/UniGene/ddd) was used to report on
significant differences in gene expression between four different
tissue pools, created from libraries of ESTs from normal prostate,
primary and metastatic prostate cancer and PIN (Wheeler et al,
2001). The data from four independent, published microarray
studies that quantified gene expression at different stages of
prostate cancer were also examined (Bubendorf et al, 1999;
Chetcuti et al, 2001; Dhanasekaran et al, 2001; Ashida et al, 2004).
Each gene was screened for the presence of a 50 CpG island using
the UCSC Human Genome Browser (http://genome.ucsc.edu/) to
positively filter for genes that could be susceptible to promoter
hypermethylation (Kent et al, 2002). Successful targets were
organised by putative function using GeneCards (http://genecards.
org) (Rebhan et al, 1997). CpG islands were characterised for
promoter sequences using Promoter Scan (http://thr.cit.nih.gov/
molbio/proscan/) (Prestridge, 1995).
Clinical sample collection
Prostate tumours and histologically normal adjacent tissue from 40
patients with primary disease, treated by radical prostatectomy at
The Adelaide and Meath Hospital (AMNCH), Dublin, Ireland, were
obtained retrospectively. Histologically normal adjacent tissue was
tissue not involved by prostate cancer, HGPIN or BPH. High-grade
prostatic intraepithelial neoplasia lesions were obtained from 14
cases. For control purposes, BPH lesions from 37 men without
prostate cancer that underwent transurethral resection (TURP) of
the prostate were also collected. Additionally, a further 39 primary
tumours were obtained from the Florida Hospital Cancer Institute,
USA (FHCI) as part of a collaboration with the National Cancer
Institute (NCI), USA. The Gleason score, TNM classification
(Fleming et al, 1997), PSA level and age at diagnosis were obtained
from the relevant clinical records. This study was approved by the
AMNCH and St James’s Hospital Ethics committee. The FHCI
specimens were approved for research purposes by the NCI Office
of Human Subjects Research.
Histological slides from the formalin-fixed, paraffin-embedded
(FFPE) surgical specimens were reviewed by a pathologist to
identify areas of histologically normal prostate, prostate cancer,
HGPIN and BPH. A series of 5mm sections were cut from the
FFPE blocks. The first tissue section from each block was
hematoxylin and eosin stained and compared with the pathologi-
cally evaluated slide, to ensure a consistent percentage of target cells.
The target cell populations were the glandular epithelial cells.
Adjacent sections were deparaffinised in xylene and rehydrated in
decreasing concentrations of ethanol. Tissue was scraped from
within the pathologically marked areas using a sterile blade and
DNA was extracted using the QIAamp DNA micro kit (Qiagen,
Crawley, UK).
Cell culture and drug treatment
Human prostate cancer cell lines LNCaP, DU145 and PC-3 and
normal prostate cell line PWR-1E were propagated under standard
cell culture conditions. The effect of DNA methylation on IGFBP3
expression was measured in LNCaP cells by treatment with the
demethylating agent 5-azacytidine. LNCaP cells (2 10
6) were
seeded in 75cm
3 culture flasks. Twenty-four hours after plating,
cells were treated with 2mM 5-azacytidine (Sigma, Dublin, Ireland)
and the medium was changed after 24h. After 2 days of treatment,
cells were harvested. DNA was isolated from cell lines by use of a
QIAamp DNA mini kit (Qiagen, UK) and total RNA was extracted
using the Trizol method (Invitrogen, Paisley, UK).
Bisulfite modification and quantitative methylation
specific PCR
Sodium bisulphite modification of genomic DNA converts
unmethylated (but not methylated) cytosines to uracils. Bisulfite
modification of approximately 20ng of DNA isolated from tissue
samples and up to 1mg of cell line DNA, was performed with the
EZ DNA methylation kit (Zymo Research, Orange, CA, USA).
Modified DNA was eluted into a final volume of 50ml1   Tris
EDTA (Sigma, Ireland).
Methylation was evaluated by real time quantitative methylation
specific PCR (QMSP) as described by Eads et al (2000). Parallel
TaqMan PCR reactions were performed on every sample with
oligonucleotides targeted to an (i) endogenous control gene
(b-actin) for unbiased amplification of bisulphite modified DNA
and (ii) target genes (GSTP1 and IGFBP3) for amplification of
bisulphite modified fully methylated molecules (Table 1). A
quantity of product was obtained for each reaction by interpola-
ting from a standard curve, constructed with 10-fold serial
dilutions of bisulfite modified, universal methylated DNA
(Chemicon International, Temecula, CA, USA). The level of
methylated target in each sample was then determined by a
relative methylation score (RMS), by applying the formula: (target
quantity/b-actin quantity) 1000.
All assays were performed in duplicate on a 7900 HT Sequence
Detection System (Perkin-Elmer, Foster City, CA, USA), in a final
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svolume of 10ml, which consisted of 2ml bisulfite-modified DNA,
primers (MWG Biotech, Ebersberg, Germany), fluorescent labelled
probe (Applied Biosystems, Warrington, UK) and 5  TaqMan
Universal PCR master mix, no AmpErase Uracil N-Glycosylase
(Roche, Branchburg, NJ, USA), under standard TaqMan real-time
PCR cycling conditions. Samples were considered positively
amplified when a comparative threshold cycle (CT) o50 was
detected in both duplicates, with o1 CT variance between
duplicates.
Methylation of IGFBP3 was investigated by three QMSP assays
designed to evaluate CpG dinucleotides at different locations
(promoter and coding sequence) within the promoter CpG island:
IGFBP3-A:  406 to  328, IGFBP3-B:  217 to  150 and IGFBP3-C:
þ132 to þ228. Altogether, the primer and probe sets covered 30/
139 CpG sites throughout the region, spanning more than 600bp of
the island.
Quantitative reverse transcription PCR
cDNA was synthesised from 1mg RNA using M-MLV reverse
transcriptase and random hexamers (Invitrogen, UK) at 371C for
1h in a total volume of 30ml. A primer and probe set was targeted
to exons 2 and 3 of the IGFBP3 gene, to avoid amplification
of DNA, forward primer 50-agtccaagcgggagacagaa-30, reverse
primer 50-caggtgattcagtgtgtcttcca-30, probe 6FAM50-ccctgccgtaga
gaa-30MGB. cDNA (100ng) was used as a template for real-time
TaqMan reactions, as described above. The levels of IGFBP3
expression in cell lines were calculated as a fold change from a
calibrator sample (normal prostate cell line PWR-1E) using the
Comparative CT method by applying the formula 2 DDCT (Livak
and Schmittgen, 2001). The amount of IGFBP3 in each sample was
normalised to an endogenous reference gene, using a b-actin
pre-developed assay (Applied Biosystems, UK).
Statistical analysis
Statistical analysis was performed using MINITAB (version 1.4).
Differences in frequencies of methylation between histologically
normal, BPH, HGPIN and prostate cancer were assessed using
Fisher’s exact Test. Differences in methylation levels of genes were
compared by examining the RMSs between samples using the
Kruskal–Wallis one-way ANOVA test and the Wilcoxon-matched
pairs test. An Unpaired t-test was used to calculate the differences
in age and PSA between patient groups. For all of the tests,
significance was ascribed at Po0.05.
RESULTS
Identification of potential targets of methylation in
prostate cancer
A list of 631 (known and unknown) genes that are downregulated
in prostate cancer was generated through our in silico strategy.
Of these genes, 355 (56.26%) possessed a CpG island within 5kb
þ/  of their transcriptional start site (Supplementary Table 1).
16/355 genes were commonly identified as downregulated in more
than one study (ATF3, CAV2, CCND2, CTSB, CYP1B1, EPB72,
GSTM1, ID2, IGFBP3, MGFE8, NET1A, OAT, RPS19, SGK, SHB and
ZFP36). The appearance of known targets of methylation, CCND2,
CD44, ECAD and GADD45A, demonstrated the success of this
technique in identifying (potential) targets of methylation in
prostate cancer. We selected IGFBP3 as our first target to evaluate.
Clinical characteristics
Methylation was investigated in tissue samples of prostate cancer,
histologically normal prostate, HGPIN and BPH. As expected, PSA
levels were higher in patients with prostate cancer (9.74ngml)
than with BPH (6.39ngml
 1)( P¼0.018, 95% CI¼1.15, 3.72),
although there was considerable overlap in the range of measures.
Notably, the mean PSA of the BPH patients was above 4.0ngml
 1,
the widely accepted upper limit of normal. The difference in mean
age between the prostate cancer (61.67 years) and BPH (75.41
years) groups was statistically significant (Po0.0001, 95%
CI¼10.50, 16.97).
IGFBP3 methylation in prostate tissues
The characterised promoter CpG island of IGFBP3 is shown in
Figure 1. IGFBP3 methylation was detected in 49/79 (62.03%) of
the prostate cancer samples at sequence A, 15/79 (19.23%) at
sequence B and 0/79 (0%) at sequence C (Figure 2).
IGFBP3 was completely unmethylated in the histologically
normal prostate samples, except for two cases that contained
methylated DNA in the IGFBP3-C region. In the BPH samples, the
frequencies of methylation were very low: IGFBP3-A, 5/37
(13.51%); IGFBP3-B, 2/37 (5.41%) and IGFBP3-C 0/37 (0%). In
total, 7/37 (18.9%) of the hyperplastic prostates showed methyla-
tion of IGFBP3, a frequency significantly less than detected in the
tumours (Po0.0001). There was no significant difference in the
methylation frequency between the histologically normal and BPH
groups.
HGPIN lesions were obtained from 14/79 patients with prostate
cancer. IGFBP3 methylation was only detected in HGPIN samples
from patients whose adjacent tumour was also methylated.
IGFBP3-A methylation was found in 7/14 (50%) cases, IGFBP3-B
in 1/14 (7.14%) cases and IGFBP3-C in 0/14 cases. The frequency of
IGFBP3 methylation in HGPIN was not statistically different from
tumour (P¼0.383).
Methylation of GSTP1 and IGFBP3
Hypermethylation of GSTP1 was identified in 75/79 (94.94%)
tumours, 10/14 (71.43%) HGPIN, 5/39 (12.82%) histologically
normal prostate samples and 4/37 (10.81%) BPH. Statistically
significant differences were found for the methylation status of
Table 1 QMSP primer and probe sequences
Primer set (50–30) forward, reverse Probe (6FAM50-30MGB) Primer, probe (nM)
b-actin ggt gga ggt agt tag ggt tta ttt gta cac ttt tat tca act aat ctc 300, 100
cca cac cac aaa atc aca ctt aac ctc att t
IGFBP3-A ttt ttt cga tat cgg ttc gtc g aga ttt tat ttc gag agc gga 300, 100
gat ctc ctt aac ccc gcc g
IGFBP3-B ggt ttc ggg cgt gcg tac tag gtg ttc gcg cga gtt t 300, 100
ccg aac tcg aaa acg tac aac tcg
IGFBP3-C Tat gta gcg ggc gcg att cgt ttt ggg tcg ttg cg 900, 300
cgc cga act cgc gc
GSTP1 gtt gcg tgg cga ttt cg cga cga ccg cta cac 300, 300
cga act ccc gcc gtc c
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normal adjacent tissues (Po0.0001). In all 49 tumours and 6/7
HGPIN that showed IGFBP3 methylation, methylation of GSTP1
was also detected. Methylation of IGFBP3 was only detected in
those samples (both tumour and the majority of HGPIN) that
demonstrated GSTP1 methylation. Notably, methylation of both
genes was not detected in any of the histologically normal or BPH
samples.
Methylation levels in prostate tissues
In addition to determining the frequencies of IGFBP3 and GSTP1
methylation, the levels of methylation were compared between the
different sample types (Figure 3). Although there was a significant
difference between the methylation levels of GSTP1 and IGFBP3
within tumour samples (Po0.0001; 95% CI¼88.17, 174.22), the
median RMS of both genes was significantly higher in tumours
than in histologically normal adjacent prostate or BPH
(Po0.0001).
Promoter hypermethylation and clinicopathologic
correlations
Results for correlations of the methylation status of IGFBP3 and
GSTP1 with clinicopathologic factors (Gleason score, TNM
classification and PSA level) are shown in Table 2. Methylation
of GSTP1 was not significantly associated with any pathological
parameters. Methylation of IGFBP3 was detected in significantly
more tumours with Gleason score X7, than p6( P¼0.01), but was
not significantly correlated with TNM classification or PSA level.
IGFBP3 methylation and gene silencing in prostate cancer
cell lines
The methylation pattern of IGFBP3 was examined in a panel of
prostate cancer cell lines (Figure 4). Only the LNCaP cell line was
found to possess methylated IGFBP3 alleles by amplification with
the A and B primer sets. The demethylation of IGFBP3 by 5-
azacytidine in this cell line was confirmed by QMSP. QRT–PCR
revealed that the three cancer cell lines expressed IGFBP3 relative
to the normal cell line PWR-1E, however, pharmacological
demethylation of LNCaP increased the expression of IGFBP3
several hundred-fold.
DISCUSSION
Recognition of the importance of promoter hypermethylation in
human cancer has fostered a growing effort to screen the cancer
genome to identify methylated loci. In this study, we describe a
novel in silico approach to identify potential targets of methylation
in prostate cancer. We employed transcriptomic databases and
microarray experiments that provided detailed data summaries
and focused on expression changes in early-stage disease (Chetcuti
et al, 2001; Ashida et al, 2004) and in the progression to metastatic
disease (Bubendorf et al, 1999; Dhanasekaran et al, 2001).
Interestingly, a common finding between these studies was that
downregulation rather than upregulation, accounted for the
majority of differentially expressed genes in prostate cancer. This
suggests that the full force of transcriptional silencing mechanisms
in prostate cancer may not yet be fully recognised.
Approximately half of the genes examined contained a 50 CpG
island, which was consistent with previous reports (Takai and
Jones, 2002; Wang and Leung, 2004). To select the most interesting
gene(s) for methylation analysis from over 300 candidates required
further validation, beyond the identification of a promoter CpG
island. Furthermore, we recognised that there are substantial
challenges in the interpretation of data obtained from large-scale
gene expression arrays. For example, which of the hundreds of
differentially expressed genes are important primary events and
which are downstream or secondary events? To maximise the
likelihood of choosing the most relevant genes for analysis,
literature review was performed on all of the candidates. This led
to the selection of the IGFBP3 gene, whose methylation status has
not been previously reported on in prostate cancer.
A detailed map of the IGFBP3 promoter CpG island facilitated
QMSP assay design around functionally relevant regions of the
island. Using three QMSP assays, we found tumour-related
differential methylation of the IGFBP3 promoter CpG island in
prostate cancer. Methylation was exclusive to the non-coding part
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Figure 1 Genomic sequence analysis of IGFBP3 (GenBank accession number M35878). The 1.2kb IGFBP3 CpG island begins 476bp upstream of the 50
untranslated region (shown in blue), extends through the first exon (shown in red) and terminates 199bp into the first intron. Putative transcription factor
binding sites that contain CpG sites are indicated. Primer and probe sequences for QMSP assays (A, B and C) are shown with black arrows and lines,
respectively.
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sof the island. The high frequency (62%) observed at the 50 end of
the island (assay-A) decreased to 19% around the MyoD, AP-2, p53
and WT-1 transcription factor binding sites (assay-B) and
diminished to zero at the start of the first exon (assay-C). Of the
15 tumours methylated at assay-B, all but one were also methylated
at the upstream part of the island, which supports the theory that
de novo hypermethylation may gradually propagate through an
island during neoplastic progression, initiating from the outer
flanks of the CpG island (Mummaneni et al, 1995; Graff et al,
1997). An interesting finding was that the majority of prostate
cancers were unmethylated around a methylation hotspot (corre-
sponding to the p-53, AP-2 and Sp-1/Sp3 binding sites), reported
in both non-small cell lung carcinoma (61%) and hepatocellular
carcinoma (33%) (Chang et al, 2002; Hanafusa et al, 2002). These
results clearly show that methylation is not uniformly spread
throughout the IGFBP3 CpG island and therefore, the choice of
CpG sites for investigation is an important consideration.
To address whether IGFBP3 methylation is involved in the early
stages of disease initiation, we examined the relationship between
methylation of IGFBP3 in prostate cancer and HGPIN isolated
from the same prostatectomy samples. Methylation was only
detected in those HGPIN lesions, whose adjacent tumour sample
from the same patient was also methylated. This implies that
hypermethylation of IGFBP3 occurs as an early event in prostate
carcinogenesis and supports a clonal relation between the tumour
and HGPIN lesion. We also found methylation of GSTP1 in a high
frequency of HGPIN foci, consistent with previous reports
(Nakayama et al, 2003; Kang et al, 2004).
Although the frequency and levels of GSTP1 methylation were
significantly higher than IGFBP3 methylation, an unexpected
finding was the concordance between methylation of both genes
across all tumours and all but one HGPIN. The high prevalence of
GSTP1 hypermethylation in prostate cancer, HGPIN and in some
proliferative inflammatory atrophy lesions indicates that it most
likely precedes many other molecular aberrations in prostate
carcinogenesis (Nakayama et al, 2003). Associated loss of GSTP1
activity and its protection from electrophilic and oxidative DNA
damage would render cells susceptible to further transformations.
Promoter hypermethylation of IGFBP3 likely occurs as a subsequent
epigenomic ‘hit’ in the multi-step process of cancer development.
Low levels of methylation were detected for both IGFBP3 and
GSTP1 in a small percentage of benign prostate samples.
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Figure 2 Differential methylation of IGFBP3 in prostate cancer. QMSP amplification plots in (A) prostate cancer, (B) HGPIN, (C) BPH and (D)
histologically normal adjacent prostate samples. Methylation was only detected in two of the morphologically normal samples at IGFBP3-C at cycle number
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quantitatively much less promoter methylation of GSTP1 in BPH
and histologically normal tissue (from tumour containing
prostates) than in cancer specimens (Jeronimo et al, 2001;
Yamanaka et al, 2003). Although every effort was taken to ensure
that tissue was only procured from within pathologically identified
areas, we cannot rule out the possibility that minute amounts of
occult carcinoma or HGPIN may have been present in some of the
benign specimens. However, even studies that employed laser
capture microdissection to isolate pure populations of cells have
reported low levels of hypermethylation in morphologically
normal prostate samples (Henrique et al, 2006). An alternative
explanation is that certain molecular aberrations such as promoter
hypermethylation may precede morphological changes, initially
affecting a small subset of benign epithelial cells. In support of this
hypothesis, none of the benign samples demonstrated any
evidence of methylation spreading, that is, they were not that
amplifiable with primer and probe sets IGFBP3-A and IGFBP3-B.
Reduced expression of IGFBP3 in the prostate epithelium is
correlated with cancer progression from HGPIN to localised cancer
and androgen-independent disease (Thrasher et al, 1996; Hampel
et al, 1998; Nickerson et al, 2001). Rising PSA levels during the
course of prostate cancer progression may facilitate tumorigenesis
by digesting IGFBP3 and releasing free IGF-1 into the prostate
microenvironment (Cohen et al, 1992). However, this post-
translational proteolysis cannot account for reduced IGFBP3
mRNA levels (Ashida et al, 2004; Thelen et al, 2004). Examination
of IGFBP3 expression in vitro, revealed that all of the prostate
cancer cell lines expressed IGFBP3, including LNCaP cells whose
methylation pattern was representative of the majority of prostate
tumours analysed (heavily methylated at IGFBP3-A, remarkably
fewer CpGs methylated at IGFBP3-B and unmethylated at IGFBP3-
C). However, 5-azacytidine treatment of LNCaP reversed the
hypermethylation pattern of IGFBP3 and resulted in a significant
induction in expression. Although these findings could indicate
monoallelic methylation in LNCaP, previous reports would suggest
that expression is maintained because methylation is not affecting
core promoter sequences (Chang et al, 2004; Hanafusa et al, 2005).
Whether methylation spreading throughout the island in approxi-
mately 20% of prostate cancers correlates with a reduction in
IGFBP3 expression, warrants further investigation.
With a shift toward earlier stages at diagnosis because of PSA
screening, it is becoming increasingly important to understand
the aetiology of prostate cancer recurrence and progression.
Table 2 Frequency of IGFBP3 and GSTP1 methylation in histologically
normal and cancerous prostate tissue, HGPIN and BPH, and relationship to
clinicopathologic factors
IGFBP3-A
n (%)
IGFBP3-B
n (%)
IGFBP3-C
n (%)
GSTP1
n( % )
Normal prostate 0/39 (0) 0/39 (0) 2/39 (5.3) 5/39 (12.82)
BPH 5/37 (13.51) 2/37 (5.41) 0/37 (0) 4/37 (10.81)
HGPIN 7/14 (50) 1/14 (7.14) 0/14 (0) 10/14 (71.43)
Prostate cancer 49/79 (62.03) 15/79 (19.23) 0/79 (0) 75/79 (94.94)
Gleason score
p6 17/37 (45.95) 4/37 (10.81) 35/37 (94.59)
X7 32/42 (76.19) 11/42 (26.19) 40/42 (95.24)
P-value 0.01 0.09 1
TNM classification
pT2 35/55 (63.64) 11/55 (20) 51/55 (94.44)
pT3, pT4 12/20 (60) 3/20 (15) 20/20 (100)
P-value 0.8 0.8 1
PSA (ngml)
o4 5/9 (55.56) 1/9 (11.11) 8/9 (88.89)
4–10 27/43 (62.79) 6/43 (13.95) 42/43 (97.67)
410 13/22 (59.1) 6/22 (27.27) 20/22 (90.91)
P-value 0.9 0.37 0.38
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Figure 4 IGFBP3 methylation and expression analyses in prostate cancer
cell lines. (A) The fold change in mRNA expression of IGFBP3 in prostate
cancer cell lines relative to normal prostate cell line PWR1E. QRT–PCR
showed that all cell lines expressed IGFBP3 mRNA but the LNCaP cell line
showed B3-fold reduction in expression. This was reversed upon
treatment with demethylating drug 5-azacytidine. (B) The relative level
of IGFBP3 methylation in cell lines was examined by QMSP and is displayed
by þþþ: 1000, þþ  : 999–500, –þ: 499–1 and —: 0.
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correlated with potentially aggressive tumours could identify those
patients more likely to recur and avoid the over-treatment of those
indolent tumours that may otherwise never require therapy. In
support of previous studies, our data show methylation of GSTP1
is highly prevalent across all grades and stages of disease
(Jeronimo et al, 2001; Yegnasubramanian et al, 2004). However,
methylation of IGFBP3 was associated with advanced tumour
grade. Increased density of methylation within a CpG island has
been associated with more advanced stages of tumours (Nosaka
et al, 2000). Although we did not detect a statistically significant
relationship between tumour samples amplified by both primer
sets IGFBP3-A and IGFBP3-B and Gleason score (P¼0.09), this
may be attributable in part to the small sample size. Non-small cell
lung carcinoma patients with methylation of IGFBP3 had
significantly poorer overall survival probability compared with
those without methylation (Chang et al, 2002). In addition,
methylation levels of IGFBP3 have been associated with tumour
recurrence in transitional cell carcinoma of the bladder (Christoph
et al, 2006). The results from this study indicate that such an
investigation is warranted in prostate cancer.
In summary, our concept of in silico data mining was successful
in identifying a novel target of frequent methylation in prostate
cancer and HGPIN. Our findings also emphasise the importance of
thorough investigations into methylation patterns in order to gain
an insight into the dynamics of de novo hypermethylation and its
relationship to transcriptional silencing. Although GSTP1 is widely
recognised as an excellent biomarker of prostate cancer, used
alone it has limitations. The inherent clinical and genetic
heterogenic nature of prostate cancer suggests that profiling the
cumulative methylation of multiple genes would serve to better
distinguish benign from malignant tissues and would provide a
more powerful approach in the early detection of prostate cancer
and in identifying those men who should be targeted for more
aggressive therapy, than characterising the status of only one gene
marker. We are screening further potential targets of methylation
that we have identified to contribute towards a methylation
fingerprint of this disease.
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